Current and future prophylactic vaccines for hepatitis C virus

Abstract: The development of a vaccine is necessary to combat the global hepatitis C virus (HCV) epidemic. The key to the development of a prophylactic vaccine is understanding the immune response in those who spontaneously resolve HCV infections versus those who develop chronic disease. Several promising vaccine candidates based on the use of viral vectors are currently in Phase I and Phase II clinical trials. The recently solved structures of the E2 glycoprotein have greatly aided epitope- and antibody-based vaccine design.

Keywords: antibody, E1E2 glycoproteins, epitope, HCV, neutralizing antibody, viral vector

Introduction

Approximately 185 million people or 2.5% of the world’s population are currently infected with hepatitis C virus (HCV), and there are 3–4 million new infections each year. A total of 60%–80% of infections will develop into chronic disease resulting in 350,000–500,000 deaths annually due to HCV-related conditions. However, many more suffer with liver cirrhosis and approximately 3% will develop hepatocellular carcinoma.

HCV is a blood-borne virus transmitted by exchange of bodily fluids. Therefore, it is most prevalent in certain populations: intravenous drug users, those receiving unscreened blood products, newborns, and those engaging in higher risk sexual activity. However, in approximately 10% of patients, the route of transmission is unclear.

A complicating factor in the treatment of the disease is the genetic diversity of the virus, which has seven distinct genotypes and at least 30% genetic sequence variability. Genotype 1 is the most common in North America, Europe, and Asia, followed by genotype 3 and then genotype 2. Genotype 4 predominates in Africa and the Middle East but has recently spread to several European countries. Genotype 6 is less prevalent and is found mainly in South and East Asia. Genotypes 5 and 7 are rarer and account for <1% of infections.

Until recently, the standard of care for all genotypes was a combination therapy of pegylated interferon and ribavirin. Side effects are universal and include fatigue, fever, and nausea with additional psychiatric effects of insomnia, headaches, irritability, and depression. Since 2011, there has been a steady stream of direct-acting antivirals (DAAs) that have been licensed for treatment. These new drugs, which inhibit viral NS5B RNA polymerase, NS3 protease, or NS5A phosphoprotein, are used alone or in combination with the existing interferon treatment and have delivered significantly higher sustained viral response rates, improved genotype coverage, and
reduced treatment times.13,14 Side effects have been reduced, and interferon-free regimens are now possible.

Major downsides of the current therapies (including the DAAs) are side effects, high cost, and the late treatment of the disease, which commonly presents after years of chronic infection. Therefore, many patients already have irreversible liver damage and possibly liver cancer. Treatment rates are low, and, with an aging population, the incidence of cirrhosis and cancer is expected to triple by 2030 in developed countries.15 Resistance to the DAAs may become an increasing problem.16 Perhaps the largest barrier to treatment is the high cost. The older interferon treatment was expensive and already out of the reach of developing nations. Some less expensive treatments may become available to poorer nations when patents expire. However, the latest combination therapies may be beyond the reach of most countries, resulting in some controversy especially as production costs are relatively low.17

Despite ground-breaking improvements in treatment, the disease burden is set to increase both in poorer and in more affluent countries. Therefore, there is a pressing need for a prophylactic vaccine to provide protection from this disease and offer a potential route for eradication.

**Virus structure and entry**

HCV is a positive-strand RNA virus that belongs to the hepacivirus genus within the larger family of Flaviviridae that includes Dengue and Yellow fever viruses. The virus RNA genome is translated as a polyprotein that is cleaved to form three structural and seven nonstructural proteins (Figure 1A). The viral nucleocapsid assembles from the core protein and contains the viral RNA genome. The nucleocapsid itself is surrounded by the virus envelope that contains covalently linked complexes of the transmembrane proteins E1 and E2.18 The surfaces of E1 and E2 are highly glycosylated containing 4 and 9–11 N-linked sites, respectively. E2 also contains four putative O-linked glycosylation sites (Figure 1B).19

The virus infects hepatocytes through a multistep process regulated by several intracellular signaling events.20 Virus particles are associated with lipoproteins, apolipoprotein E (ApoE), high-density lipoprotein, and low-density lipoprotein to form lipoviral particles. The entry process requires four essential receptors and coreceptors: scavenger receptor BI (SR-BI), CD81, and two tight junction proteins, claudin-1 and occludin. SR-BI is the first receptor to interact, initially with ApoE on the lipoviral particle and subsequently more directly with E2. The virus is taken into the cell via clathrin-mediated endocytosis and fuses with the endosomal membrane prior to uncoating and release of the viral genome.21 Until recently, E2 was believed to be a class II fusion protein, similar to those of other flaviviruses, and to mediate this fusion event. However, recent crystal structure data showed that E2 does not adopt

---

**Figure 1** HCV genome organization, polyprotein processing, and glycoprotein structure.

**Notes:** (A) The 9.6 kb positive sense RNA genome encodes a single ORF flanked by structured 5’ and 3’ UTRs. IRES-mediated translation yields a polyprotein precursor that is co- and posttranslationally processed to produce three structural and seven nonstructural proteins. (B) Schematic representation of the envelope glycoproteins E1 and E2. Numbers indicate amino acid positions in the HCV polyprotein of reference strain H, genotype 1a (GenBank accession no AF009606). N followed by a number indicates the position of N-linked glycans, shown as green trees. HVR-1 and HVR-2, the IgVR, and the TMD are shown.

**Abbreviations:** HCV, hepatitis C virus; ORF, open reading frame; UTRs, untranslated regions; IRES, internal ribosome entry site; HVR-1, hypervariable region 1; HVR-2, hypervariable region 2; IgVR, intergenotypic variable region; TMD, transmembrane domain; +ve, positive.
the extended conformation of class II fusion proteins but has a compact, globular structure.22,23 The N terminus of E1 also has an unexpected fold and is unlikely to mediate class II fusion.24 The molecular detail of the roles of E1 and E2 in the fusion event is therefore unclear and will likely involve a novel entry mechanism.

**Protective immune responses to HCV**

**Humoral responses**

After initial infection by HCV, virus can be detected in serum after 1–3 weeks, but neither HCV-specific T-cells nor antibodies are detectable for 1–2 months. This delay in adaptive responses may contribute to the chronicity of HCV.25–27 It is widely accepted that cellular responses can resolve acute infection but the role of neutralizing antibodies (nAbs) in this regard is less clear.28 Several studies have shown that individuals can clear HCV infection without an effective humoral response, showing that nAbs are not absolutely required. Nevertheless, nAbs appear to be important in the control of chronic infection and prevention of reinfection.29,29–33 In one example, depletion of serum antibody (Ab) resulted in higher viremia and worsening of the disease and restoration of Ab levels resulted in disease improvement.34

Recent work has provided stronger evidence for nAbs in the resolution of acute infection. The early generation of high-titer broadly neutralizing Ab (bnAb) is associated with clearance of acute infection, whereas the later appearance of low-titer nAb with limited cross-reactivity is found in chronic disease.35–38 The role of Abs in protection from infection by HCV has also been demonstrated by passive immunization in animal models and in human beings.39–41 In human beings, this was observed in an incident involving a commercial intravenous immunoglobulin (IVIG) product prepared from pooled human plasma and used to treat primary immunodeficiency. After the introduction of screening by testing for HCV antibodies, one batch of the IVIG, from which units containing anti-HCV had been excluded, transmitted HCV to patients.42 The product was unfortunately contaminated with HCV, and the exclusion of plasma containing anti-HCV made it more infectious than earlier batches of IVIG made from unscreened plasma. Due to the protection provided by passive immunization, clinical trials are now proceeding to test the efficacy of HCV nAbs to prevent reinfection in liver transplant patients.43

**Cellular responses**

As with the humoral response, cellular responses to infection are delayed, and resolution of acute infection only occurs after the appearance of HCV-specific T-cells expressing IFN in the liver.44–47 The infection is met with a broad and strong helper T-cell (CD4+) and cytolytic T-cell (CD8+) response, which weakens and narrows in chronic disease.48,49 HCV-specific helper T-cells are difficult to detect in chronic disease, and the reason for their loss is poorly understood.50–52 CD8+ cells are also lost early in viral persistence, although this may be an adaptive response to prevent further tissue damage.53 Pathways leading to the loss or exhaustion of HCV-specific CD8+ cells may involve several factors, including the loss of CD4+ cells, viral mutation and chronic antigen stimulation, and also the appearance of regulatory T-cells.28

The requirement for both CD4+ and CD8+ cells in the resolution of infection has been demonstrated in an animal model where chimpanzees that previously cleared the infection were reinfected after the removal of one subset or the other.54,55 Cytotoxic T-cell activity (T-cell perforin expression and hepatocyte apoptosis) can also be correlated with disease resolution in the chimpanzee model, implying a role for this cell type.56

In summary, spontaneous resolution of infection is associated with an early adaptive immune response in the form of high-titer nAb and also a broad, strong, and sustained T-cell response where both helper and cytotoxic T-cells are absolutely required.

**Vaccine approaches**

Depending on race, age, genetics, and disease status, 20%–40% of individuals, after initial infection, eradicate the disease over a period of weeks or months.2,57 This has provided optimism that prophylactic vaccination to harness natural immunity could also be effective. Overall results using therapeutic vaccines have been disappointing, with only small reductions in viral loads, and therefore a prophylactic vaccine may be a more achievable target. A widely accepted goal of HCV treatment is the prevention of chronicity of infection, and this may be easier to achieve in uninfected subjects prophylactically than reverse it in infected patients with therapeutic vaccination. A confusing term in this regard is sterilizing immunity, which is commonly associated with prophylactic vaccination. Sterilizing immunity may be impossible to achieve with HCV, and more likely, a period of infection (or reinfection after future exposures) will precede viral clearance after prophylactic vaccination, similar to the scenario documented for patients who spontaneously resolve the disease.

So far, the development of a pan-genotypic vaccine to HCV has been challenging, mainly due to the genetic diversity of the virus. However, a vaccine that protected against
a single common genotype would be a major advance. Another genetic problem for vaccine design is the high viral replication and mutation rate. The virus exists in the body as a constantly evolving quasispecies or vast swarm of closely related but distinct structures. This diversity presents particular problems for the humoral immune response and production of nAbs, which are the basis of all successful viral vaccines to date. HCV has also evolved a variety of strategies to evade antibody-mediated neutralization such as hypervariable regions (HVRs) within the envelope glycoproteins that act as immunological decoys (Table 1). How then can the immune system or a vaccine elicit a broadly neutralizing response to such an elusive target? One solution for vaccine development may be to focus on conserved epitopes. This strategy has also recently been adopted in vaccine design for human immunodeficiency virus (HIV) to overcome similar challenges of viral diversity and variability. Some rare bnAbs against HIV have been found after patient screening that are highly divergent from germline variable sequences, presumably having undergone extensive affinity maturation, and it has been suggested that novel vaccination strategies will be required to elicit them. This may also be the case for HCV, and one strategy that has been predicted to yield results is sequential vaccination with different but related antigens to more precisely direct the immune system. Advances of in-silico modeling will greatly aid the design of novel immunogens to mimic chosen epitopes. Additionally, next-generation sequencing means detailed analysis of the immune responses to vaccines is possible, and this will enable researchers to track the affinity maturation of particular B-cell lineages that could elicit bnAb.

**Prophylactic B-cell vaccines**

Early vaccine research on HCV began exploiting the potential of the envelope glycoproteins E1 and E2. This approach produced some promising results in animal models. Substantial evidence of this approach comes from a meta-analysis of vaccine studies in chimpanzees, which concluded that structural proteins were better than nonstructural proteins at eliciting a protective response. This implies that nAbs are important to clear infection.

Immunization of healthy volunteers with recombinant E1E2 heterodimer induced cross-reactive nAb responses to genotypes 1a, 1b, and 2a, but development of this vaccine is on hold because of the difficulty of producing intact recombinant heterodimer. The difficulty of producing recombinant protein can be overcome by heterologously expressing envelope glycoproteins in a viral vector or virus-like particle (VLP). Although the whole molecule approach shows some promise, it may fail due to same viral evasion strategies that contribute to chronic infection (Table 1). An appropriately modified E2 protein, for example, without HVRs, may avoid viral evasion strategies and ultimately be a more successful candidate. However, folding issues may limit the use of singly expressed or modified E2 proteins. Some recent research in chimpanzees failed to generate a nAb response using E2 lacking the HVR-1 region. The same work also demonstrated that only E1-vaccinated animals and not E2-vaccinated animals cleared HCV infection. In a Phase I clinical trial using a similar strategy, recombinant E1 generated low-to-moderate Ab responses alongside a clear T-helper 1 response in nearly all participants.

In summary, the use of whole glycoproteins can generate bnAb responses, although there have been mixed results using recombinant singly expressed E1 and E2.

**Prophylactic T-cell vaccines**

Most HCV vaccines have been designed as therapeutic strategies and have focused on nonstructural epitopes to generate cellular (T-cell) responses. However, there are several promising prophylactic T-cell vaccine candidates that have progressed to clinical trials.

One recent approach used adenoviral particles expressing the NS3–NS5 region of genotype 1b to generate long-lasting...

---

**Table 1** Viral evasion strategies to avoid antibody-mediated neutralization

<table>
<thead>
<tr>
<th>Viral evasion strategy</th>
<th>Outcome</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Delay of the adaptive immune response</td>
<td>Virus can establish infection</td>
<td>28</td>
</tr>
<tr>
<td>High genetic variability</td>
<td>Emergence of immune-escape mutants</td>
<td>59</td>
</tr>
<tr>
<td>Highly glycosylated envelope</td>
<td>Antibody epitopes are shielded by glycans</td>
<td>60</td>
</tr>
<tr>
<td>Glycan shifting</td>
<td>Alteration of local conformation abrogates nAb binding</td>
<td>61</td>
</tr>
<tr>
<td>Antibody interference</td>
<td>nAb cannot bind to epitopes or neutralize virus</td>
<td>68</td>
</tr>
<tr>
<td>Immunodominant hypervariable regions</td>
<td>Immune response targets non-neutralizing epitopes</td>
<td>62,63</td>
</tr>
<tr>
<td>Cell to cell transmission</td>
<td>Virus hidden from antibodies</td>
<td>64</td>
</tr>
<tr>
<td>Viral particles associate with lipoproteins</td>
<td>Antibody epitopes are shielded in lipoviral particles</td>
<td>65–67</td>
</tr>
</tbody>
</table>

**Abbreviation:** nAb, neutralizing antibody.
T-cell responses in healthy volunteers. This novel strategy used the adenoviral vectors human adenovirus 6 (Ad6) and chimpanzee adenovirus 3 (ChAd3), both containing DNA encoding the same region of the HCV genome. The immune system was primed with an initial inoculation of Ad6, and then boosted with several inoculations of ChAd3. These particular adenoviruses were chosen based on rare serotypes to reduce antivector immune responses, although such responses may have limited boosting in this study. The T-cell responses were predominately cytotoxic although helper T-cells were also present. T-cell responses were triggered by peptides from genotypes 1b, 1a, and to a lesser extent 3a, demonstrating a potentially wide treatment profile. Importantly, responses were also strong in a standard enzyme-linked immunospot (ELISPOT) assay measuring IFN-γ (>1,000 SFC/10^6 peripheral blood mononuclear cells). A later study trial using ChAd3 as the priming vector and modified vaccinia Ankara (MVA) as the boosting vector had arguably an even better T-cell response profile. As previously, long-term memory T-cells were present but also higher CD4+ cell levels and even higher CD8+ cell responses. This was possibly due to lower immune responses to the MVA virus particles used for boosting. In addition, the authors carried out a more in-depth study of T-cell subsets to show a vaccination profile similar to that seen in other successful viral vaccines or in natural immunity. The next step is to discover if these responses are protective against infection. Phase I and Phase II trials to assess safety and efficacy are due for completion in 2016 (Table 2). The same strategy is also being tested in a Phase I/II trial as a therapy for HCV-infected patients, and it will be interesting to compare efficacy of these very promising viral vector stratagems. Two other viral vector vaccine strategies using

### Table 2: Current prophylactic vaccine candidates

<table>
<thead>
<tr>
<th>Type of immune response targeted</th>
<th>Sponsor</th>
<th>Vaccine formulation</th>
<th>Stage of development</th>
<th>Year</th>
<th>Lead author</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Humoral (B-cell)</td>
<td>Chiron/Novartis</td>
<td>rE1E2/MF59</td>
<td>Chimpanzee (n=7)</td>
<td>1994</td>
<td>QL Choo</td>
<td>74</td>
</tr>
<tr>
<td></td>
<td>Chiron/Novartis</td>
<td>rE1E2/MF59</td>
<td>Human being (n=60)</td>
<td>2010</td>
<td>SE Frey</td>
<td>76</td>
</tr>
<tr>
<td>Fujirebio Europe</td>
<td>BPRC</td>
<td>rE1/Alum or rE2/Alum</td>
<td>Chimpanzee (n=4)</td>
<td>2011</td>
<td>BE Verstrepen</td>
<td>81</td>
</tr>
<tr>
<td>Cellular (T-cell)</td>
<td>Intercell AG</td>
<td>IC41 (core, NS3, NS4 peptides)/poly-L-arginine</td>
<td>Human being (n=60)</td>
<td>2008</td>
<td>CS Klade</td>
<td>93</td>
</tr>
<tr>
<td></td>
<td>Intercell AG</td>
<td>IC41 (core, NS3, NS4 peptides)/poly-L-arginine</td>
<td>Human being (n=54)</td>
<td>2010</td>
<td>C Firbas</td>
<td>94</td>
</tr>
<tr>
<td></td>
<td>CSL Ltd/Novartis</td>
<td>Core/iSCOMATRiX</td>
<td>Human being (n=30)</td>
<td>2009</td>
<td>D Drane</td>
<td>95</td>
</tr>
<tr>
<td></td>
<td>Okairos Co</td>
<td>Ad6/Ad24+ electroporated DNA</td>
<td>Chimpanzee (n=4)</td>
<td>2006</td>
<td>A Folgori</td>
<td>90</td>
</tr>
<tr>
<td></td>
<td>Okairos Co</td>
<td>Ad6/ChAd32</td>
<td>Rhesus macaque (n=3)</td>
<td>2006</td>
<td>E Fattori</td>
<td>91</td>
</tr>
<tr>
<td></td>
<td>University of Oxford/Okairos Co</td>
<td>Ad6/ChAd3 (NS3, NS4, NS5)</td>
<td>Human being (n=30)</td>
<td>2012</td>
<td>E Barnes</td>
<td>84</td>
</tr>
<tr>
<td></td>
<td>NIAID</td>
<td>ChAd3/MVA</td>
<td>Human being (Phase I, n=68; Phase II, n=382)</td>
<td>2016</td>
<td>No authors listed</td>
<td>88</td>
</tr>
<tr>
<td>Humoral and cellular (B- and C-cell)</td>
<td>NIH/Okairos Co</td>
<td>Ad/DNA</td>
<td>Chimpanzee (n=5)</td>
<td>2012</td>
<td>SH Park</td>
<td>92</td>
</tr>
<tr>
<td></td>
<td>Transgene</td>
<td>DNA encoding E1, E2, and NS3 plus MVA encoding E1, E2, and NS3</td>
<td>Chimpanzee (n=4)</td>
<td>2007</td>
<td>CS Rollier</td>
<td>98</td>
</tr>
<tr>
<td></td>
<td>NIH</td>
<td>VLP (core, E1, E2)/AS01B</td>
<td>Chimpanzee (n=4)</td>
<td>2007</td>
<td>GA Elmoualid</td>
<td>100</td>
</tr>
<tr>
<td></td>
<td>NYC Blood Center</td>
<td>Recombinant vaccinia encoding E1, E2, P7, NS2, and NS3</td>
<td>Chimpanzee (n=4)</td>
<td>2008</td>
<td>JH Youn</td>
<td>99</td>
</tr>
</tbody>
</table>

**Notes:** Vaccines were classified as humoral (B-cell) if they contained recombinant E1, E2, E1–E2 heterodimer, or DNA encoding these proteins. Vaccines were classified as cellular (T-cell) if they did not contain recombinant E1, E2, E1/E2 heterodimer, or DNA encoding these proteins.

**Abbreviations:** Ad, adenovirus; numbers indicate type; ChAd, adenovirus of chimpanzee origin; BPRC, Biomedical Primate Research Centre, Holland; NIAID, National Institute of Allergy and Infectious Disease, Bethesda, USA; NIH, National Institute of Health, USA; DNA, Plasmids containing hepatitis C virus genetic material; n, number of subjects used in the study; rE1 or rE2, recombinant E1 or E2 protein; rE1E2, recombinant E1E2 heterodimer; VLP, virus-like particle; MVA, modified vaccinia Ankara; MF59, AS01B, iSCOMATRiX, proprietary adjuvants.
Adenoviruses are also currently being developed. In summary, the above vaccine strategies using viral vectors have great potential. However, formulating a vaccine with two different components may be expensive, and repeated boosting may not be practical in the developing world and for some patient groups.

Another vaccine candidate being developed for both prophylaxis and therapy uses synthetic peptides derived from the core, NS3, and NS4 proteins that have been chosen to stimulate both cytotoxic and helper T-cells. Participants for this modality of treatment will occasionally have to be human leukocyte antigen (HLA) matched to the peptides used for vaccination. HLA classes that bind to the peptides present in a vaccine can be predetermined experimentally and by computer analysis. This should generate optimal immune responses in selected patients for a particular set of peptides. Volunteers for this study were previously-treated HCV patients who possessed the HLA-A 0201 allele, which is present in 50% of Caucasians. The results from two clinical trials in healthy volunteers showed that response was correlated with higher peptide doses and the use of adjuvants (poly L-arginine). However, the strength of the responses was very weak when compared to viral vector and VLP systems and there is no information on long-term memory responses. The company aims to develop this vaccine with a broader range of epitope targets and different adjuvants. This should help to increase the strength and breadth of T-cell responses achieved by this vaccine approach.

A third vaccine candidate designed to elicit protective cellular responses against the core protein has also reached clinical trials. This strategy involves injecting the core protein, expressed in yeast, with a novel proprietary adjuvant composed of saponin, phospholipid, and cholesterol that forms spherical micelle-like structures. In a Phase I trial, nearly all participants developed antibodies to the core protein, but T-cell responses were only present in two volunteers (25%) receiving the highest dose of vaccine. These trial results were disappointing given previous promising results in a Rhesus macaque model. This approach, which is also being considered as a therapy for chronically infected patients, will have to achieve high T-cell responder rates. Further trials are planned with higher doses of vaccine.

**Prophylactic B- and T-cell combined vaccines**

For a successful outcome, B-cell vaccines that contain recombinant protein or peptide from E1 and/or E2 may have to be combined with a T-cell vaccine and heterologously expressed. This would increase the possibility of a strong, broad, and sustained humoral and cellular response. Another option is for the vaccine to contain both B- and T-cell epitopes. Three vaccines that contain both B- and T-cell HCV epitopes have been tested in the chimpanzee. Two are based on strains of vaccinia virus and a third on a VLP (Table 2).

A prime and boost regimen using DNA and MVA encoding E1E2 and NS3 has been developed. However, T-cell responses were transient and three of four animals were not protected from challenge with HCV.

An HCV-based VLP vaccine encoding core, E1, and E2 has been developed by the National Institute of Health (USA). A high HCV-specific T-cell response was induced in four animals that were protected against subsequent challenge with a homologous strain. A lower dose to weight ratio in this study compared to previous mouse vaccinations may explain the lack of a humoral response. The high T-cell responses in this study show promise that this versatile vector may be developed into a successful vaccine approach.

A lack of humoral response was also a characteristic of a vaccinia virus vaccine that encoded structural and nonstructural proteins. This vaccine, developed by the New York City Blood Center, induced a moderate T-cell response in four animals, and there was 100% protection from chronic disease after challenge with the same genotype. Some cross-genotypic protection was also found after combined challenge with six genotypes.

In summary, results from B- and T-cell combined vaccines have been mixed. In general, they have elicited good cellular responses and poor humoral responses.

**New targets for future HCV vaccines**

**NABs and key epitopes for vaccine design**

Recent crystal structures of E2 peptides and of truncated E2 protein complexed to bnAb have provided a starting point to design immunogens that elicit epitope-specific antibodies. Some bnAbs bind to conserved linear epitopes, and these are of great interest because technically it is to easier to make an immunogen that represents a linear rather than a discontinuous epitope. However, nearly all the well-characterized bnAbs bind to discontinuous epitopes on E2 that are proposed to form part of the CD81 binding site. Extensive work has provided evidence for three main CD81 binding regions on the surface of E2 (regions 1–3 described later; Figure 2).68,103,104 BnAbs binding to these regions prevent E2 association with CD81 and presumably subsequent viral entry and fusion. Our understand-
The compact structure consists of a central β-sandwich flanked by front and back layers consisting of flexible loops and helices. To allow folding and crystallization, the N and C termini and also internal HVRs were omitted. Despite this, several areas of protein were disordered, including a key CD81 binding region (region 1). It has been proposed that a nontruncated E2, folded in the presence of E1, would adopt a slightly different structure with a different arrangement of disulfide bonds. Nevertheless, the structure shows that the proposed CD81 binding regions are juxtaposed on one face of the molecule (Figure 3). Notwithstanding these limitations, knowledge of the structure of E2 has rekindled interest in exploiting conserved neutralizing epitopes for vaccine design.

Key epitopes for vaccine design
Region 1
The region between residues 412 and 423, immediately downstream of HVR-1, contains some highly conserved amino acid (aa) residues that are recognized as a series of overlapping epitopes by a number of monoclonal antibodies (Figure 2). One such antibody is the mouse monoclonal AP33, which inhibits infection in cell culture models of HCV and neutralizes virus of all genotypes in HCV pseudoparticle (HCVpp) assays. A humanized, affinity-matured version of AP33 (MRCT10.v362) has an approximately threefold higher neutralization potency on three tested genotypes. Therefore, this region is an exciting prospect for vaccine design.

The AP33 epitope has been characterized by alanine-scanning mutagenesis and X-ray crystallography (Figure 3). The major determinants of antibody recognition are residues Leu 413, Asn 415, Gly 418, and Trp 420. The latter is a contact residue for all bnAbs that recognize this region and is critical for binding of E2 to CD81. The structures of three antibody–peptide complexes with bnAbs AP33, HCV1, and hu5B3.v3 show this region forming a β-hairpin structure. A fourth antibody–peptide complex of the same region with bnAb
3/11 shows the peptide adopting a very different, extended conformation. A fifth complex reveals a composite structure comprising a looser turn and extended conformation. Therefore, it would appear that this region of E2 can adopt different conformations and is likely to be flexible. Indeed, this region is disordered in the crystal structure.

Interestingly, this segment of E2 appears to have low antigenicity in HCV-infected patients and only 2.5% of patient sera tested positive to a peptide mimic. However, a vaccine based on this region could be much more antigenic and generate a stronger antibody response. Antibody-resistant mutants have been found by passaging HCV in the presence of bnAb AP33 in cell culture, which could indicate limitations of the protective effect of AP33-like antibodies in vivo. Encouragingly, another bnAb (HC-33) that is more resistant to immune escape has been isolated to this epitope. A combined immunogen based on the AP33 and HC-33 binding sites is an attractive prospect, as it raises the possibility of a vaccine that elicits a pan-genotypic bnAb response that is resistant to escape mutants.

Region 2
The region of E2 encompassed by aa residues 434–446 (Figures 2 and 3) was previously thought to elicit mainly antibodies that inhibited neutralization by bnAbs specific for region 1. However, the recent discovery of bnAbs that bind to this region has shown that, although some interference between binding and neutralization to either region is possible, there can also be additive or synergistic neutralization when bnAbs to both regions are present. The structure of this region has been determined both in the context of E2 core and as antibody-bound peptides. It consists of a long N-terminal loop and a short C-terminal helix of 1.5 turns. However, the angle and local conformation of the loop and helix vary in different structures and this has been interpreted to mean that region 2 can adopt different conformations, which may reflect different functional binding states of E2. Antibodies binding to this region can either be neutralizing or non-neutralizing depending on which conformation is bound. The short alpha helix contains the highly conserved aa residues Phe 442 and Tyr 443, which are implicated in binding to a hydrophobic pocket formed by the large extracellular loop on CD81. The series of HC-84 antibodies that recognize this region have broad genotype specificity and some bind to linear epitopes. No immune-escape variants arose when the virus was passaged in the presence of the HC-84 series of bnAbs, showing that they are resistant to virus escape from neutralization. This region is another good target for an epitope-focused vaccine approach.

Region 3
This region, comprising aa residues 523–535, has been proposed as a major binding site for CD81 that is also recognized by several bnAbs, some of which are effective across all the common genotypes (Figures 2 and 3). It includes the highly conserved residues Tyr 527, Trp 529, Gly 530, and Asp 535 that have been identified by alanine-scanning mutagenesis as being critical for CD81 binding. Characterization of antibody recognition determinants using a variety of methods has provided evidence for contact with one or more of these highly conserved residues in a number of overlapping epitopes. However, recent structural data conflict with some of the previous mutagenesis findings. The structure of the AR3C-E2 complex shows that the bnAb AR3C does not contact residues Gly 530 and Asp 535, as indicated previously by alanine scanning, and that its major binding site is region 2 and not region 3 as previously reported. This may also be the case for other bnAbs such as CBH-5 that are predicted, on the basis of alanine scanning, to share the same recognition residues. It is likely that mutagenesis in this region changes the conformation of E2 and prevents antibody recognition at other sites. The major contact residue in this region for AR3C based on the crystal structure data is Trp 529, which, together with other proposed CD81 binding residues, would contribute to a hydrophobic interface (Figure 3). This segment of E2 appears to be relatively antigenic, and antibodies to it have been found in patient sera and in mice immunized with E2, although much of these data have been generated by alanine scanning and may not be reliable. This region also appears to be resistant to the emergence of escape variants and would be another good prospect for an epitope-based vaccine, although some uncertainty exists in the residues involved in antibody and CD81 binding.

Region 4
Early mutagenesis studies highlighted a small region between aa residues 611 and 617 as a potential CD81 binding site. This finding has been supported by the characterization of the interaction sites of several bnAbs such as the HC-84 series and HC-11 (Figure 2). The tryptophan (W) present within this region (YPYRLWH) is a contact residue for some of the HC-84 series of bnAbs based on structural analysis and mutagenesis and could contribute to a hydrophobic interface for CD81 binding (Figure 3). This small segment of E2 is
recognized by conformational antibodies, and any peptide-based vaccine would likely have to include other regions, described earlier, to allow antibody binding.

**Other neutralizing epitopes**

Two other regions have been described recently that are recognized by bnAb and which are not part of the CD81 binding site. These areas, termed antigenic regions 4 and 5 by Giang et al, are formed in the heterodimer by clusters of residues in a relatively unstudied part of E2 close to the membrane and perhaps also by residues in E1. The authors speculate that the epitopes are located at an interface between the two envelope proteins and are present only in the correctly folded E1E2 complex. Further characterization of these newly discovered epitopes is required to assess their prospects for vaccine design.

**Future prospects**

The potential of small conserved regions of E2 in a vaccine has been largely unexplored in human clinical studies. One approach could be immunization with peptides in combination with a suitable adjuvant. The peptide structure could be changed chemically, for example, by cyclization or possibly linked to a chemical or protein scaffold. Such changes of the natural structure could improve stability and antigenicity; a key issue with protein vaccination methods. A scaffold also offers the possibility of presenting multiple peptides in the correct orientation to mimic a discontinuous epitope in the native E2 structure. Such a strategy has been used to make a potential vaccine candidate for Respiratory Syncytial Virus. In this case computer modelling was used to design an immunogen that mimics the structure and orientation of an epitope bound by a well characterized nAb. A few animal studies have also used free peptides containing conserved epitopes of E2 to explore their potential to generate a humoral response. In one study, vaccination of mice with a T-cell helper epitope linked to peptide sequences generated nAb that inhibited entry of genotype 1a pseudoparticles into Huh-7 cells. In summary, the use of peptide antigens to mimic HCV structural epitopes has achieved mixed vaccination results. However, new technologies to improve stability, antigenicity, and orientation mean that they could still form part of a successful novel vaccination strategy. One approach would be to combine a peptide vaccine with another type of antigen such as a subunit vaccine with a prime and boost regimen to focus the immune system on particular epitopes.

The conserved epitopes could also be exploited using an anti-idiotype approach (Figure 4). In this strategy, a bnAb is used as the starting point to reverse-engineer a vaccine. By judicious screening, an antibody can be isolated whose variable regions mimic the shape of the original epitope. This antibody or a derived fragment of it is used as a vaccine. This novel vaccination approach has been used to treat cancer and is currently being developed for HCV.

The epitopes could also be presented in a VLP or virus construct. This strategy has been used to express whole or truncated surface E1 and E2 in a vaccine context, but expression of the small conserved HCV epitopes in such constructs is unexplored. One platform that could be tested is a hepatitis B virus (HBV) VLP. Two different HBV VLPs are available, formed from either the core protein or the HBV surface antigen (HBVSAg). The HBV core protein that forms the capsid of the virus has proven to be a very flexible carrier of heterologous inserts. B- and T-cell epitopes have been inserted at the N and C termini as well as the major immunodominant region of the core protein in numerous vaccination experiments. Strong T-cell (helper and cytotoxic) responses are developed against the HBV core protein, and, given that cellular and humoral responses are both important in controlling HCV infection, the possibility of inserting HCV B- and T-cell
epitopes into a HBV core protein is an intriguing one. The flexibility, high antigenicity, and compatibility with nearly any recombinant expression system make HBV core VLPs a very good candidate for an epitope-based vaccine for HCV. Although HBV core-based VLP vaccines have not progressed past the preclinical stage for HCV, two other HBV core-based vaccines have progressed to clinical testing for malaria and influenza A. 135-137 Another possibility utilizing HBV is the insertion of HCV epitopes into the HBVSAg, which can also self-assemble with host lipids into VLPs without the nucleocapsid and is the basis of the successful worldwide HBV vaccine. In the field of HCV, this system has grounds for optimism as some recent work swapping the TM region of E1 and E2 with HBVSAg produced VLPs that induced high-titer nAb when used as a vaccine in an animal model. 78,138 Many other VLP approaches using different platforms are also possible. 101 

A completely different approach would be the use of viral vectors. Viral vectors based on adenovirus or vaccinia could be used to express E2 epitopes in a standalone strategy or used in a prime-boost regimen when combined with E2 protein or peptides. A study in mice using Ad6 expressing full length and truncated E1E2 was combined in a prime and boost regimen with recombinant E1E2 protein to elicit strong cellular and bnAb responses. A similar approach using canary pox virus and the HIV surface protein gp120 has been the most successful HIV vaccine to date. 139

Summary

Recent DAAs have revolutionized the therapeutic treatment of hepatitis C. However, the disease burden is still set to increase in developed and developing countries. A prophylactic vaccine could circumvent treatment issues such as late diagnosis, high costs, and provide an eradication route for this disease.

Immune correlates of protection deciphered from studying spontaneous resolvers and chronic patients have provided important clues to the potential attributes of a successful vaccine, although more work needs to be done to define this further.

The most advanced HCV vaccine to date involves the use of viral vectors with a prime and boost regimen. Notably, a similar strategy has led to the currently most successful HIV vaccine.

Recent crystal structures of the HCV envelope glycoprotein E2 have renewed interest in a rational vaccine approach to design immunogens that mimic conserved epitopes on E2.

Acknowledgment

The work in the authors’ laboratory is funded by the Medical Research Council, UK.

Disclosure

The authors report no conflicts of interest in this work.

References


139. Vaccari M, Poonam P, Franchini G. Phase III HIV vaccine trial in Healthy Adults (FLU-A) [Internet]. 2014.
